February 2023 Issue Table Of Contents

From The Editor

• Choosing Your Battles

Feature Articles

• Why Takeda Is Focusing So Much On Plasma-Derived Therapies
• With Fundraising, A Track Record Matters: GeoVax’s David Dodd

CEO Corner

• Driving And Sustaining Innovation In Biopharma Today
• My Journey From "Science Guy" To CEO

Companies To Watch

• Corner Therapeutics

Industry Research

• Clinical Manufacturing Volume By Service Provider Category

Podcast Summary

• Where Oncology Treatment Goes Next

Inside The Industry

• Why Life Sciences Change-Management Initiatives Fail
• How A Robust R&D Pipeline Can Safeguard Innovation
• The Collaborative Crisis: How Pharma Can Shake Up Its Silos
• Clinical Manufacturing Outsourcing Practices Are in Flux
• Scientist-Founders Reshape The Bio Biz
• The Modernization Of Life Sciences RIM
• Persistent Noncompliance Leads To A Consent Decree
• How Portage Biotech Created A Lean, New Drug Development Model
• 7 Risk Management Mistakes To Avoid For Life Sciences Startups

Leadership Lessons

• Celebrating Quiet Leadership

Ask The Board

• Do You Think That Biopharmaceutical Companies Receiving An FDA Accelerated Approval Should Be Required To Enroll Patients In A Confirmatory Study Prior To Launch?
• What Tips Would You Give To An Early-Stage Biopharma CEO Preparing To Present New Clinical Data At A Medical Meeting?